Crossmark

Performance-Based Risk-Sharing Arrangements (PBRSA): Is it a Solution to Increase Bang for the Buck for Pharmaceutical Reimbursement Strategy for Our Nation and Around the World?

Crossref DOI link: https://doi.org/10.1007/s40261-020-00972-w

Published Online: 2020-10-09

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Andy Eunwoo

Choi, David Hohyun

Chang, Jongwha

Kim, Sean Hyungwoo https://orcid.org/0000-0002-4520-8994
License Information

Text and Data Mining valid from 2020-10-09

Version of Record valid from 2020-10-09
More Information

Article History

Accepted: 20 September 2020

First Online: 9 October 2020

Declarations

:

: No funding was obtained for this study.

: Andy Eunwoo Kim, David Hohyun Choi, Jongwha Chang and Sean Hyungwoo Kim report no conflict of interest in this work.

: Not applicable in this review.

: Not applicable in this review.

: Not applicable in this review.

: Not applicable in this review.

: Not applicable in this review.

: Andy Eunwoo Kim and David Hohyun Choi were responsible for idea and draft writing for the manuscript. Jongwha Chang was responsible for formatting and editing the overall manuscript. Sean Hyungwoo Kim was responsible for idea, draft writing, and overall supervision of the editing, manuscript writing, as well as all the support for literature search and providing resources.

Document is current

Any future updates will be listed below